UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
35474,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2024/01/26/2818073/0/en/CONDITIONS-FOR-RIKSBANK-AUCTIONS-GOVERNMENT-BONDS.html,CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS,Bid procedure  2024-02-02BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01SWEDEN I/L BOND: 3114  SE0013748258  2030-06-01¬†Bid date2024-02-02Bid......,Bid procedure  2024-02-02 Bonds SWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01SWEDEN I/L BOND: 3114  SE0013748258  2030-06-01Bid date 2024-02-02 Bid times 09.00-10.00 (CET/CEST) on the Bid date Offered volume (corresponding nominal amount) 3113: 200 million SEK +/-200 million SEK3114: 200 million SEK +/-200 million SEKHighest permitted bid volume (corresponding nominal amount) 3113: 200 million SEK per bid3114: 200 million SEK per bidLowest permitted bid volume (corresponding nominal amount) SEK 10 million per bid Expected allocation time Not later than 10.15 (CET/CEST) on the Bid date Delivery and payment date 2024-02-06 Settlement amount To be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANKStockholm  2024-01-26This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version  the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.,neutral,0.02,0.95,0.04,neutral,0.01,0.98,0.01,True,English,"['RIKSBANK AUCTIONS GOVERNMENT BONDS', 'CONDITIONS', 'Highest permitted bid volume', 'Lowest permitted bid volume', 'SWEDEN I/L BOND', 'Euroclear Sweden AB', 'RIKSSESS ALERT acronym', 'Swedish language version', 'corresponding nominal amount', 'securities settlement system', 'Bid date Delivery', 'Settlement amount', 'payment date', 'Bid procedure', 'Bid times', '200 million SEK', 'CTM BIC', 'special terms', 'Complete terms', 'VPCSSESSXXX Account', 'English translation', '02 Bonds', 'allocation', 'Riksbank', 'SWIFT', 'Stockholm', 'conditions', 'case', 'inconsistency']",2024-01-26,2024-01-27,globenewswire.com
35475,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/currency/AUSTRALIAN-DOLLAR-EURO-AU-2361412/news/Europe-must-not-weaponize-euro-ECB-policymaker-warns-45819715/,Europe must not weaponize euro  ECB policymaker warns,(marketscreener.com) The euro zone should notweaponize its own currency in a global conflict as that couldultimately undermine it  an influential European Central Bankpolicymaker said on Friday  just as the EU was contemplatingseizing Russian state assets‚Ä¶,"RIGA  Jan 26 (Reuters) - The euro zone should not weaponize its own currency in a global conflict as that could ultimately undermine it  an influential European Central Bank policymaker said on Friday  just as the EU was contemplating seizing Russian state assets.European officials have been debating for months whether to confiscate frozen Russian assets  including central bank reserves  to use the cash to fund Ukraine's reconstruction.But some are concerned that the broader repercussions of such a move  from retaliation to loss of confidence in European assets  will far outweigh the gain.""Weaponizing a currency inevitably reduces its attractiveness and encourages the emergence of alternatives "" Bank of Italy Governor Fabio Panetta said in a speech without directly referring to Russia. ""This power must be used wisely  however  because international relations are part of a ‚Äòrepeated game'.""The EU  United States  Japan and Canada froze some $300 billion of Russian central bank assets in 2022 when Russia invaded Ukraine. Some $200 billion of that is held in Europe  mainly in the Belgian clearing house Euroclear.Opponents argue that seizing assets could prompt investors from other countries to flee  fearing for the safety of their own investments  ultimately weakening the currency and pushing up yields.Panetta  a former ECB board member  argued that the conflict around Ukraine had led to an increase in the role of the Chinese renminbi at the expense of other currencies  since much of Russia's trade is now done in the Chinese currency.""The Chinese authorities are explicitly promoting its role on the global stage and encouraging its use in other countries  including those sanctioned by the international community following the invasion of Ukraine "" Panetta said.As a result  the renminbi overtook the euro as the second most used currency for trade finance and the yen as the fourth most used currency for global payments  Panetta said.Panetta instead argued that Europe should strengthen the euro by making it more attractive  implementing long-delayed changes that would enhance its role as a reserve currency.This includes the creation of a safe asset that is issued in sufficient  predictable quantities  and the completion of a banking union that would the reduce the difficulty of cross-border banking. Another step would be an efficient payment and market infrastructure system across the bloc  he said. (Reporting by Balazs Koranyi; editing by Christina Fincher)",negative,0.03,0.22,0.75,negative,0.03,0.27,0.71,True,English,"['ECB policymaker', 'Europe', 'influential European Central Bank policymaker', 'former ECB board member', 'Russian central bank assets', 'central bank reserves', 'Belgian clearing house', 'sufficient, predictable quantities', 'Russian state assets', 'frozen Russian assets', 'Governor Fabio Panetta', 'European assets', 'European officials', 'broader repercussions', 'international relations', 'repeated game', 'United States', 'other countries', 'other currencies', 'Chinese authorities', 'global stage', 'international community', 'global payments', 'long-delayed changes', 'safe asset', 'banking union', 'cross-border banking', 'efficient payment', 'infrastructure system', 'Balazs Koranyi', 'Christina Fincher', 'global conflict', 'The EU', 'Chinese renminbi', 'trade finance', 'euro zone', 'Chinese currency', 'reserve currency', 'RIGA', 'Reuters', 'Friday', 'months', 'cash', 'Ukraine', 'reconstruction', 'move', 'retaliation', 'loss', 'confidence', 'gain', 'attractiveness', 'emergence', 'alternatives', 'Italy', 'speech', 'power', 'part', 'Japan', 'Canada', 'Euroclear', 'Opponents', 'investors', 'safety', 'investments', 'yields', 'increase', 'role', 'expense', 'invasion', 'result', 'second', 'yen', 'fourth', 'creation', 'completion', 'difficulty', 'step', 'market', 'bloc']",2024-01-26,2024-01-27,marketscreener.com
35476,EuroNext,NewsApi.org,https://www.marketwatch.com/story/lvmh-leads-luxury-shares-rally-following-record-2023-results-despite-market-slump-19912b2f,LVMH leads luxury shares rally following record 2023 results despite market slump,LVMH Moet Hennessy Louis Vuitton‚Äôs Paris listed shares surged on Friday following the luxury firm‚Äôs decision to hike its dividend on the back of record 2023...,LVMH Moet Hennessy Louis Vuitton‚Äôs Paris listed shares surged on Friday following the luxury firm‚Äôs decision to hike its dividend on the back of record 2023 results  in a rally that lifted shares across the luxury sector amid a slowdown that has pummeled the industry in recent months.The Paris headquartered conglomerate  which owns top brands including Christian Dior and Tiffany & Co  saw its sales surge 10% in the fourth quarter  to ‚Ç¨23.9 billion ($26 billion)  in an uptick that saw its full-year revenue reach all-time highs of ‚Ç¨86.2 billion.Shares in LVMH MC  +12.81% that are listed on the Euronext Paris stock exchange rallied 8% on Friday having lost 8% of their value over the previous 12 months.LVMH‚Äôs results saw its net income increase 8%  to ‚Ç¨15.2 billion  as its sales grew across all segments of its business aside from its wine & spirits division  which includes cognac brand Hennessy and champagne seller Mo√´t & Chandon.Luxury goods companies including Hermes International RMS  +6.63%   Kering KER  +6.59%   Christian Dior CDI  +12.04%   and Prada 1913  +2.24% also saw their share prices lifted by the rally  following a tough year for the sector which has been hard hit by a drop in consumer spending following the end of a boom during COVID-19.LVMH CEO Bernard Arnault said the company is now entering 2024 with ‚Äúconfidence ‚Äù despite signs that growth in the company‚Äôs sales had started to slow in the second half of 2023 in the face of an increasingly uncertain macroeconomic and geopolitical environment.The slowdown in the latter half of 2023 saw LVMH‚Äôs sales grow at rates of just 9% in the third quarter and 10% in the final three months of 2023  compared to bumper rates of 17% in both the first and second quarter of the year.In a call with investors  Arnault  however  said he expects LVMH‚Äôs sales will be boosted in 2024 by the lowering of interest rates and the upcoming U.S. elections  as he noted previous elections have had a ‚Äúpositive impact‚Äù on LVMH‚Äôs business.LVMH‚Äôs results follow Arnault‚Äôs decision to nominate his two sons  Alexandre  31  and Fr√©d√©ric  29  for positions on the luxury conglomerate‚Äôs board of directors  in a move that is set to further consolidate the family‚Äôs control over the company.In 2023  Arnault previously lost his position as the world‚Äôs richest person  after being overtaken by Amazon founder Jeff Bezos  following a dip in LVMH‚Äôs share price due to the global slowdown in demand for luxury goods.The LVMH chief  who has a net worth of $164 billion  now sits in third place on Bloomberg‚Äôs Billionaire Index behind both Bezos and Tesla CEO Elon Musk.The company said it would also call on the board to hike LVMH‚Äôs dividend  from rates of ‚Ç¨7.50 a share to ‚Ç¨13 a share.Citi analysts led by Thomas Chauvet said they expect LVMH‚Äôs sales will continue to rise at a low-single-digit percentage over 2024. ‚ÄúThis should be enough to support the shares near-term which have lagged slightly this year to date and in the past 3 months ‚Äù Citi‚Äôs analysts said.,neutral,0.23,0.72,0.04,negative,0.02,0.3,0.68,True,English,"['luxury shares rally', 'record 2023 results', 'LVMH', 'market', 'slump', 'LVMH Moet Hennessy Louis Vuitton', 'Tesla CEO Elon Musk', 'Euronext Paris stock exchange', 'upcoming U.S. elections', 'The Paris headquartered conglomerate', 'LVMH CEO Bernard Arnault', 'cognac brand Hennessy', 'Hermes International RMS', 'Fr√©d√©ric', 'net income increase', 'The LVMH chief', 'final three months', 'Paris listed shares', 'Christian Dior CDI', 'Luxury goods companies', 'luxury conglomerate', 'previous elections', 'net worth', 'recent months', 'previous 12 months', 'past 3 months', 'luxury firm', 'top brands', 'fourth quarter', 'full-year revenue', 'time highs', 'spirits division', 'champagne seller', 'Mo√´t', 'Kering KER', 'share prices', 'consumer spending', 'second half', 'uncertain macroeconomic', 'geopolitical environment', 'latter half', 'third quarter', 'second quarter', 'positive impact', 'two sons', 'richest person', 'Amazon founder', 'third place', 'Billionaire Index', 'Thomas Chauvet', 'low-single-digit percentage', 'LVMH MC', 'luxury sector', 'tough year', 'bumper rates', 'interest rates', 'Jeff Bezos', 'record 2023 results', 'global slowdown', 'sales surge', 'Citi analysts', 'Friday', 'decision', 'dividend', 'back', 'rally', 'industry', 'uptick', 'value', 'segments', 'business', 'wine', 'Chandon', 'Prada', 'drop', 'boom', 'COVID', 'company', 'confidence', 'signs', 'growth', 'face', 'first', 'call', 'investors', 'lowering', 'Alexandre', 'positions', 'board', 'directors', 'move', 'family', 'control', 'world', 'dip', 'demand', 'Bloomberg', 'date', '2024']",2024-01-26,2024-01-27,marketwatch.com
35477,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/01/26/2817634/0/en/Bekaert-Update-on-the-Share-Buyback-Program.html,Bekaert - Update on the Share Buyback Program,Update on the Share Buyback Program    Period from 18¬†January 2024 to 24¬†January 2024    On 17 November 2023  Bekaert announced the start of...,Update on the Share Buyback ProgramPeriod from 18 January 2024 to 24 January 2024On 17 November 2023   Bekaert announced the start of the eighth tranche of its buyback program  for a total maximum consideration of up to ‚Ç¨ 30 million (the Eighth Tranche). All shares bought as part of the Program will be cancelled. The purpose of the Program is to reduce the issued share capital of the company.Bekaert announces today that during the period from 18 January 2024 to 24 January 2024  Kepler Cheuvreux on behalf of Bekaert has bought 47 848 shares.The table below provides an overview of the transactions under the eighth of the Program during the period from 18 January 2024 to 24 January 2024:Repurchase of shares Date Market Number of Shares Average Price paid (‚Ç¨) Highest Pricepaid (‚Ç¨) Lowest Pricepaid (‚Ç¨) TotalAmount (‚Ç¨) 18 January 2024 Euronext Brussels 9 348 44.61 44.86 44.24 417 014 MTF CBOE MTF Turquoise MTF Aquis 19 January 2024 Euronext Brussels 10 000 45.06 45.40 44.74 450 600 MTF CBOE MTF Turquoise MTF Aquis 22 January 2024 Euronext Brussels 10 000 45.33 45.70 45.00 453 300 MTF CBOE MTF Turquoise MTF Aquis 23 January 2024 Euronext Brussels 10 000 45.36 45.68 45.10 453 600 MTF CBOE MTF Turquoise MTF Aquis 24 January 2024 Euronext Brussels 8 500 45.31 45.48 45.08 385 135 MTF CBOE MTF Turquoise MTF Aquis Total 47 848 45.14 45.70 44.24 2 159 649On 24 January 2024 after closing of the market  Bekaert holds 2 322 706 own shares  or 4.24% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.08,0.91,0.01,negative,0.01,0.29,0.7,True,English,"['Share Buyback Program', 'Bekaert', 'Update', 'MTF CBOE MTF Turquoise MTF Aquis Total', 'total maximum consideration', 'Share Buyback Program Period', 'investor relations pages', 'Date Market Number', 'Shares Average Price', 'total number', 'share capital', 'Highest Price', 'Lowest Price', 'Kepler Cheuvreux', 'Euronext Brussels', 'eighth tranche', 'outstanding shares', '47 848 shares', 'Update', '18 January', '24 January', '17 November', 'Bekaert', 'start', 'part', 'purpose', 'company', 'behalf', 'table', 'overview', 'transactions', 'Repurchase', 'Amount', 'closing', 'information', 'website', 'Attachment', '2 322 706']",2024-01-26,2024-01-27,globenewswire.com
35478,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/LUMIBIRD-5001/news/LUMIBIRD-FINANCIAL-COMMUNICATIONS-AGENDA-45822796/,LUMIBIRD: FINANCIAL COMMUNICATIONS AGENDA -January 26  2024 at 10:11 am EST,(marketscreener.com) Lannion  January 26  2024 FINANCIAL COMMUNICATIONS AGENDA LUMIBIRD [FR0000038242 ‚Äì LBIRD]  the European leader for laser technologies  publishes its financial communications agenda for 2024. ¬†Disclosure dateClosed periodFY 2023 revenuesMo‚Ä¶,Lannion  January 26  2024FINANCIAL COMMUNICATIONS AGENDALUMIBIRD [FR0000038242 ‚Äì LBIRD]  the European leader for laser technologies  publishes its financial communications agenda for 2024.Disclosure date Closed period FY 2023 revenues Monday 29/01/2024 FY 2023 earnings Tuesday 12/03/2024 from 12/02/2024 to 12/03/2024 included Q1 2024 revenues Monday 22/04/2024 Annual Shareholders Meeting Tuesday 29/04/2024 H1 2024 revenues Monday 22/07/2024 H1 2024 earnings Tuesday 24/09/2024 from 24/08/2024 to 24/09/2024 included Q3 2024 revenues Monday 21/10/2024*after close of tradingThe agenda is indicative and may be subject to change.Closed periods  prior to the publication of earnings  during which no trading in the Company's shares is permitted  apply to managers  persons assimilated to managers and any person who has access on a regular or occasional basis to inside information of the Company.Next date: 2023 full-year revenue on January 29  2024 after close of tradingLUMIBIRD is one of the world's leading specialists in lasers. With 50 years of experience and a mastering of solid state laser  laser diodes and fiber laser technologies  the Group designs  manufactures and markets high performance lasers for scientific (laboratories and universities)  industrial (manufacturing  defense  Lidar sensors) and medical (ophthalmology  ultrasound diagnostic) markets.Born from the combination of Keopsys Group with Quantel in October 2017  LUMIBIRD has more than 1 000 employees and over ‚Ç¨191 million of consolidated revenues in 2022 and is present in Europe  America and Asia.LUMIBIRD shares are listed on the Euronext Paris B Compartment. FR0000038242 ‚Äì LBIRD www.lumibird.comSince 2022  LUMIBIRD is part of Euronext Tech LeadersContactsLUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17 00info@lumibird.com LUMIBIRDSonia RutnamChief Financial and Transformation OfficerTel. +33(0) 1 69 29 17 00info@lumibird.com CalyptusMathieu CalleuxInvestors RelationsTel. +33(1) 53 65 37 91lumibird@calyptus.netAttachment,neutral,0.02,0.97,0.01,neutral,0.02,0.96,0.01,True,English,"['FINANCIAL COMMUNICATIONS AGENDA', 'LUMIBIRD', 'January', '10:11', 'Mathieu Calleux Investors Relations', 'Euronext Paris B Compartment', 'Euronext Tech Leaders', 'Annual Shareholders Meeting', 'Marc Le Flohic', 'solid state laser', 'FINANCIAL COMMUNICATIONS AGENDA', 'fiber laser technologies', 'high performance lasers', 'Chief Financial', 'laser diodes', 'European leader', 'Disclosure date', 'FY 2023 revenues', 'Q1 2024 revenues', 'H1 2024 revenues', 'Q3 2024 revenues', 'Closed periods', 'occasional basis', 'Next date', '2023 full-year revenue', 'leading specialists', 'Lidar sensors', 'medical (ophthalmology', 'ultrasound diagnostic', 'consolidated revenues', 'Sonia Rutnam', 'Transformation Officer', 'FY 2023 earnings', 'H1 2024 earnings', 'Keopsys Group', 'LUMIBIRD shares', 'Lannion', 'January', 'LBIRD', '12/02', 'trading', 'change', 'publication', 'Company', 'managers', 'persons', 'access', 'regular', 'information', 'world', '50 years', 'experience', 'mastering', 'scientific', 'laboratories', 'universities', 'industrial', 'manufacturing', 'defense', 'markets', 'combination', 'Quantel', 'October', '1 000 employees', 'America', 'Asia', 'Contacts', 'Chairman', 'CEO', 'Tel.', 'Calyptus', 'Attachment']",2024-01-26,2024-01-27,marketscreener.com
35479,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/FERMENTALG-16118042/news/Fermentalg-After-EUR4m-in-sales-in-2023-Fermentalg-kicks-off-2024-with-over-EUR9m-in-contract-45819690/,Fermentalg : After EUR4m in sales in 2023  Fermentalg kicks off 2024 with over EUR9m in contracts and orders -January 26  2024 at 02:35 am EST,(marketscreener.com)  Libourne - January 25  2024 - Fermentalg  the French leader in microalgae listed on Euronext   today unveils its 2023 sales figures and 2024 outlook  fueled by orders and commercial contracts at an all-time high at the start of the fin‚Ä¶,"Libourne - January 25  2024 - Fermentalg  the French leader in microalgae listed on Euronext (FALG)  today unveils its 2023 sales figures and 2024 outlook  fueled by orders and commercial contracts at an all-time high at the start of the financial year.This new sales momentum is the first fruit of the 2024 - 2026 strategic plan unveiled at the end of 2023[1] in favor of profitable  sustainable growth.Thanks to this roadmap focused on accelerating sales  developing strategic partnerships and continuous innovation  Fermentalg should consolidate its position as European leader in sustainable solutions based on marine microalgae biotechnology  with sales target of ‚Ç¨10 million in 2024 and over ‚Ç¨25 million by 2026  compared with ‚Ç¨4 million in 2023[2] .90% of 2024 sales target already securedThe new sales policy introduced in the summer of 2023 aims both to win over new customers  particularly in market segments that are under- or unaddressed  and to establish long-term relationships with them via framework contracts to ensure visibility and recurring sales. As a result  the sum of annual orders and contracts has risen from less than ‚Ç¨1 million at the start of 2023 to over ‚Ç¨9 million today  representing a more than 10-fold increase in 12 months.Three new customers in each of the major geographical regions illustrate  with contracts of over ‚Ç¨1 million  the needs of industrial customers in response to consumer expectations. One is a diversified specialist in food ingredients  while another  a player in marine Omega-3s  is introducing a microalgae-based range to its portfolio. The latter is based in Asia  where demand for microalgae-based products is strong in response to concerns about the possible contamination of fish oils by radioactive waste from Fukushima.Growth expected in Q1 and new opportunities to boost momentumThis excellent start to the year should enable Fermentalg to post strong sales growth as early as 1st quarter 2024. Beyond that  the Company has levers to maintain and amplify this momentum throughout the year.Fermentalg has begun discussions with several new prospects  each representing several million euros in potential annual sales  including:In infant formulas  a strategic segment for which Fermentalg has marketing authorizations in Europe and the United States.In the field of high-concentration Omega-3  where Fermentalg has unrivalled legitimacy with an oil concentrated up to 620mg/g of DHA.Fermentalg will also benefit from the planned ramp-up  over the coming months  of its new strategic partnership with the HuvePharma group[3] . This alliance will enable the Company to offer feed and food industry players the only source of algal omega-3 in the European Union  and an oil that meets the highest standards in terms of quality  competitiveness  and environmental performance.Next publication: full-year results 2023 andsales for str quarter 2024  April 3  2024 (after market close)About FermentalgAn expert in the research and bioindustrial exploitation of microalgae  Fermentalg aims to offer sustainable solutions and innovative products that contribute to the development of healthy  natural and high-performance products. Our business: the development  production and marketing of sustainable solutions and active ingredients derived from microalgae  for nutrition  health and the environment. Nutritional lipids  alternative proteins  natural food colorings and innovative environmental solutions make up our company's current and future offering. Fermentalg shares are listed on Euronext Paris (FR0011271600 - FALG)  and are eligible for PEA-PME and long-only SRD. It has received an Exemplary rating (90/100) from EthiFinance ESG Ratings  a rating agency specializing in the ESG performance of SMEs listed on European markets  in favor of Socially Responsible Investment (SRI).For further information: www.fermentalg.comContact for journalists: Investor Relations : ACTUS finance and communicationFatou-Kin√© N'DIAYETelephone: +33 (0)1 53 67 36 34fndiaye@actus.fr ACTUS finance and communicationJ√©r√¥me FABREGUETTES LEIBTelephone: +33 (0)1 53 67 36 78fermentalg@actus.fr[1] New strategic plan 2024 - 2026 and major industrial partnership // Acceleration towards a profitable and sustainable growth model[2] Unaudited sales of ‚Ç¨4.058m for fiscal 2023[3] Through its subsidiaries HuveNutra and BiovetThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: yWmflciXlmaUm55tZZ1mbGlmmGhpl5bFmmGWlpRqlMzKnWpilG5maMqcZnFknW5q- Check this key: https://www.security-master-key.com .Regulated information:Inside Information:- Information on annual revenues Full and original press release in PDF: https://www.actusnews.com/news/83894-falg_cp_ca_2023_en.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2024 ActusNews",neutral,0.17,0.8,0.03,mixed,0.56,0.25,0.18,True,English,"['Fermentalg', 'sales', 'EUR9m', 'contracts', 'orders', 'January', 'J√©r√¥me FABREGUETTES LEIB', 'major geographical regions', 'several million euros', 'Socially Responsible Investment', ""Fatou-Kin√© N'DIAYE"", 'original press release', 'several new prospects', 'food industry players', 'EthiFinance ESG Ratings', 'major industrial partnership', 'next press releases', 'natural food colorings', 'new strategic partnership', 'Three new customers', 'new sales policy', 'sustainable growth model', 'strong sales growth', 'SECURITY MASTER Key', 'New strategic plan', 'potential annual sales', 'Actusnews SECURITY MASTER', 'innovative environmental solutions', 'marine microalgae biotechnology', 'profitable, sustainable growth', 'new sales momentum', '2026 strategic plan', 'industrial customers', 'new opportunities', 'food ingredients', 'sustainable solutions', 'marine Omega-3s', 'environmental performance', 'innovative products', 'healthy, natural', 'ESG performance', 'strategic partnerships', 'strategic segment', 'annual revenues', '2023 sales figures', 'sales target', 'recurring sales', 'Unaudited sales', 'French leader', 'first fruit', 'continuous innovation', 'European leader', 'long-term relationships', '10-fold increase', 'consumer expectations', 'diversified specialist', 'microalgae-based range', 'microalgae-based products', 'possible contamination', 'fish oils', 'radioactive waste', '1st quarter', 'infant formulas', 'United States', 'high-concentration Omega-3', 'unrivalled legitimacy', 'HuvePharma group', 'algal omega-3', 'European Union', 'highest standards', 'Next publication', 'full-year results', 'str quarter', 'bioindustrial exploitation', 'high-performance products', 'active ingredients', 'Nutritional lipids', 'alternative proteins', 'future offering', 'Exemplary rating', 'rating agency', 'European markets', 'Investor Relations', 'annual orders', 'commercial contracts', 'market segments', 'framework contracts', 'marketing authorizations', 'coming months', 'Euronext Paris', 'ACTUS finance', 'Regulated information', 'Inside Information', 'financial year', 'excellent start', 'Fermentalg shares', '12 months', 'Libourne', 'January', 'FALG', '2024 outlook', 'time', 'end', 'favor', 'roadmap', 'position', 'summer', 'visibility', 'needs', 'response', 'portfolio', 'Asia', 'demand', 'concerns', 'Fukushima', 'Q1', 'Company', 'levers', 'discussions', 'field', '620mg', 'DHA', 'ramp-up', 'alliance', 'feed', 'source', 'terms', 'quality', 'competitiveness', 'April', 'expert', 'research', 'development', 'business', 'production', 'current', 'PEA-PME', 'SRD', 'SMEs', 'SRI', 'Contact', 'journalists', 'communication', 'Telephone', 'fndiaye', 'Acceleration', 'fiscal', 'subsidiaries', 'HuveNutra', 'Biovet', 'yWmflciXlmaUm55tZZ1mbGlmmGhpl5bFmmGWlpRqlMzKnWpilG5maMqcZnFknW5q', 'PDF', 'cp', 'email']",2024-01-26,2024-01-27,marketscreener.com
35480,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SIGNIFY-N-V-27862555/news/Signify-quarterly-results-in-line-but-forecasts-disappoint-45820620/,Signify: quarterly results in line  but forecasts disappoint -January 26  2024 at 05:37 am EST,(marketscreener.com) Signify published quarterly results on Friday that were broadly in line with expectations  but its forecasts for 2024 were disappointing  and the stock was down 4% by mid-morning on the Amsterdam Stock Exchange.The Dutch lighting speciali‚Ä¶,Signify: quarterly results in line  but forecasts disappointJanuary 26  2024 at 05:37 am EST ShareSignify published quarterly results on Friday that were broadly in line with expectations  but its forecasts for 2024 were disappointing  and the stock was down 4% by mid-morning on the Amsterdam Stock Exchange.The Dutch lighting specialist reported fourth-quarter sales of 1.73 billion euros  down 12.3% on a reported basis.Net profit came to 59 million euros  compared with 86 million euros a year earlier.While analysts welcomed the comfortable amount of free cash flow generated by the company last year - 586 million euros compared with 445 million in 2022 - they considered its outlook somewhat disappointing.For 2024  Signify said it was aiming for an adjusted Ebitda margin 0.5 percentage points better than the 10% recorded for the full year 2023  while it ended the fourth quarter with a margin of 12%.And while the Group also announced an increase in its annual dividend  from 1.50 to 1.55 euros  the share was sulked Friday morning on Euronext Amsterdam  posting a 4.4% drop at 11:30 a.m.Copyright (c) 2024 CercleFinance.com. All rights reserved.,negative,0.02,0.15,0.83,negative,0.0,0.02,0.98,True,English,"['quarterly results', 'Signify', 'line', 'forecasts', 'January', '05', 'The Dutch lighting specialist', 'free cash flow', 'Amsterdam Stock Exchange', 'Euronext Amsterdam', 'quarterly results', 'fourth-quarter sales', 'Net profit', 'comfortable amount', 'full year', 'fourth quarter', 'annual dividend', '1.73 billion euros', 'Ebitda margin', '86 million euros', '1.55 euros', '59 million', 'Signify', 'line', 'forecasts', 'January', 'Share', 'Friday', 'expectations', 'mid-morning', 'basis', 'analysts', 'company', 'outlook', 'Group', 'increase', '4.4% drop', 'Copyright', 'CercleFinance', 'rights', '05', '37', '1.50', '11:30']",2024-01-26,2024-01-27,marketscreener.com
35481,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/AB-SCIENCE-6133795/news/AB-Science-announces-an-update-in-the-marketing-authorization-application-of-masitinib-in-amyotrophi-45823535/,AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency,(marketscreener.com) PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE SE‚Ä¶,"PRESS RELEASEAB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCYA DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE SECOND QUARTER OF 2024Paris  26 January  2024  6pm CETAB Science SA (Euronext ‚Äì FR0010557264 ‚Äì AB) announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure  instead of addressing these issues through the Oral Explanation.At D195 of the procedure  certain major objections remained  and an Oral Explanation was scheduled on January 24  2024 to address these objections.This week  before the date planned date of the Oral Explanation  the CHMP has proposed that AB Science addresses these objections in writing instead of the Oral Explanation.AB Science has accepted this proposal  which is unusual at this stage of the procedure  as it offers AB Science the possibility of giving more detailed responses than what would be possible during an Oral Explanation  and provides CHMP with more time to evaluate the responses. A new Oral Explanation is not mandatory and will be scheduled only if major objections remain after the review of the written responses.AB Science now expects an opinion from the CHMP in the second quarter of 2024.About AB ScienceFounded in 2001  AB Science is a pharmaceutical company specializing in the research  development and commercialization of protein kinase inhibitors (PKIs)  a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs  often lethal with short term survival or rare or refractory to previous line of treatment.AB Science has developed a proprietary portfolio of molecules and the Company‚Äôs lead compound  masitinib  has already been registered for veterinary medicine and is developed in human medicine in oncology  neurological diseases  inflammatory diseases and viral diseases. The company is headquartered in Paris  France  and listed on Euronext Paris (ticker: AB).Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based  statements based on projects  objectives  intentions and expectations regarding financial results  events  operations  future services  product development and their potential or future performance.These forward-looking statements can often be identified by the words ""expect""  ""anticipate""  ""believe""  ""intend""  ""estimate"" or ""plan"" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable  investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed  induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or  more generally  any factors that may affect marketing capacity of the products developed by AB Science  as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements  subject to the applicable regulations  in particular articles 223-1 et seq. of the AMF General Regulations.For additional information  please contact:AB ScienceFinancial Communication & Media Relationsinvestors@ab-science.comAttachment",neutral,0.02,0.98,0.01,mixed,0.07,0.3,0.63,True,English,"['marketing authorization application', 'amyotrophic lateral sclerosis', 'European Medicines Agency', 'AB Science', 'update', 'masitinib', 'high unmet medical needs', 'AMYOTROPHIC LATERAL SCLEROSIS', 'EUROPEAN MEDICINES AGENCY', 'protein kinase inhibitors', 'short term survival', 'other similar terms', 'AMF General Regulations', 'MARKETING AUTHORIZATION APPLICATION', 'new Oral Explanation', 'AB SCIENCE ANNOUNCES', 'AB Science SA', 'applicable regulations', 'marketing authorizations', 'marketing capacity', 'PRESS RELEASE', 'SECOND QUARTER', '6pm CET', 'Human Use', 'written response', 'targeted proteins', 'previous line', 'proprietary portfolio', 'lead compound', 'veterinary medicine', 'human medicine', 'historical facts', 'future services', 'future performance', 'forward-looking information', 'competent authorities', 'public documents', 'additional information', 'Financial Communication', 'Media Relations', 'neurological diseases', 'inflammatory diseases', 'viral diseases', 'product development', 'Medicinal Products', 'Outstanding Issues', 'major objections', 'Forward-looking Statements', 'financial results', 'numerous risks', 'actual events', 'detailed responses', 'pharmaceutical company', 'Euronext Paris', 'UPDATE', 'MASITINIB', 'DECISION', '26 January', 'Committee', 'CHMP', 'List', 'D195', 'procedure', 'writing', 'proposal', 'stage', 'possibility', 'time', 'review', 'opinion', 'research', 'commercialization', 'PKIs', 'class', 'action', 'pathways', 'cells', 'programs', 'treatment', 'molecules', 'oncology', 'France', 'projections', 'estimates', 'assumptions', 'projects', 'objectives', 'intentions', 'expectations', 'operations', 'potential', 'words', 'investors', 'uncertainties', 'control', 'factors', 'obligation', 'undertaking', 'particular', 'articles', 'Attachment', '2024']",2024-01-26,2024-01-27,marketscreener.com
35482,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SMCP-S-A-38166115/news/SMCP-Q4-sales-and-2023-landing-45823417/,SMCP - Q4 sales and 2023 landing,(marketscreener.com) Press release - Paris  January 26th  2024 Q4 Sales remain stable in a deteriorated macro-economic environmentReduction of debt and inventories  while maintaining full-price strategy2023 landing revised In the fourth quarter of 2023  Group‚Ä¶,Press release - Paris  January 26th  2024Q4 Sales remain stable in a deteriorated macro-economic environmentReduction of debt and inventories  while maintaining full-price strategy2023 landing revisedIn the fourth quarter of 2023  Group sales remained stable compared to 2022 at constant exchange rates  despite a macro-economic context that continued to deteriorate: heightened geopolitical tensions  weak household consumption and persistent inflation.The good resilience of the Group in the United States offset a difficult month of December in Europe (particularly in France) and a less dynamic month than expected in China. Despite those headwinds  the Group decided to maintain a very strict discount policy.Taking these elements into account  SMCP expects a performance slightly below previous announcement:sales around ‚Ç¨1.230m 1 ie. a growth at constant FX of +3.8% vs 2022 (previously ‚Äúmid-single digit growth‚Äù);ie. a growth at constant FX of +3.8% vs 2022 (previously ‚Äúmid-single digit growth‚Äù); adjusted EBIT margin between 6.4% and 6.6%1 of sales (previously ‚Äú7% to 9% of sales‚Äù).In the meantime  the Group accelerated its savings plan and continued to make financial strength a priority:Decrease of year-end net financial debt;Good level of liquidity maintained;Reduction of inventories compared to 2022.During the presentation scheduled on February 28th  the Group will communicate further details about 2023 annual performance and the continuation of the savings plan for 2024.DISCLAIMER: FORWARD-LOOKING STATEMENTSCertain information contained in this document includes projections and forecasts. These projections and forecasts are based on SMCP management's current views and assumptions. Such forward-looking statements are not guarantees of future performance of the Group. Actual results or performances may differ materially from those in such projections and forecasts as a result of numerous factors  risks and uncertainties. These risks and uncertainties include those discussed or identified under Chapter 3 ‚ÄúRisk factors and internal control‚Äù of the Company‚Äôs Universal Registration Document filed with the French Financial Markets Authority (Autorit√© des March√©s Financiers - AMF) on 11 April 2023 and available on SMCP's website (www.smcp.com).This document has not been independently verified. SMCP makes no representation or undertaking as to the accuracy or completeness of such information. None of the SMCP or any of its affiliate‚Äôs representatives shall bear any liability (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document.***ABOUT SMCPSMCP is a global leader in the accessible luxury market with four unique Parisian brands: Sandro  Maje  Claudie Pierlot and Fursac. Present in 47 countries  the Group comprises a network of over 1 600 stores globally and a strong digital presence in all its key markets. Evelyne Chetrite and Judith Milgrom founded Sandro and Maje in Paris  in 1984 and 1998 respectively  and continue to provide creative direction for the brands. Claudie Pierlot and Fursac were respectively acquired by SMCP in 2009 and 2019. SMCP is listed on the Euronext Paris regulated market (compartment A  ISIN Code FR0013214145  ticker: SMCP).CONTACTSINVESTORS/PRESS SMCP BRUNSWICK Am√©lie Dernis Hugues Bo√´ton Tristan Roquet Montegon +33 (0) 1 55 80 51 00 +33 (0) 1 53 96 83 83 amelie.dernis@smcp.com smcp@brunswickgroup.com1 Non audited figuresAttachment,neutral,0.01,0.99,0.0,mixed,0.21,0.22,0.56,True,English,"['Q4 sales', 'SMCP', '2023 landing', 'INVESTORS/PRESS SMCP BRUNSWICK Am√©lie Dernis Hugues Bo√´ton Tristan Roquet Montegon', 'Autorit√© des March√©s Financiers', 'four unique Parisian brands', 'French Financial Markets Authority', 'year-end net financial debt', 'Euronext Paris regulated market', 'accessible luxury market', 'weak household consumption', 'strict discount policy', 'strong digital presence', 'audited figures Attachment', 'less dynamic month', 'constant exchange rates', 'single digit growth', 'Such forward-looking statements', 'Universal Registration Document', 'financial strength', 'key markets', 'difficult month', 'constant FX', 'Press release', 'January 26th', 'macro-economic environment', 'full-price strategy', 'fourth quarter', 'macro-economic context', 'geopolitical tensions', 'persistent inflation', 'good resilience', 'United States', 'previous announcement', 'EBIT margin', 'savings plan', 'Good level', 'February 28th', 'current views', 'Actual results', 'numerous factors', 'Risk factors', 'internal control', 'global leader', 'Claudie Pierlot', 'Evelyne Chetrite', 'Judith Milgrom', 'creative direction', 'compartment A', 'ISIN Code', 'SMCP management', '2023 annual performance', 'future performance', 'Q4 Sales', 'Group sales', 'deteriorated', 'Reduction', 'inventories', '2023 landing', 'December', 'Europe', 'France', 'China', 'headwinds', 'elements', 'account', 'meantime', 'Decrease', 'liquidity', 'presentation', 'details', 'continuation', 'DISCLAIMER', 'information', 'projections', 'forecasts', 'assumptions', 'guarantees', 'performances', 'risks', 'uncertainties', 'Chapter', 'Company', 'AMF', '11 April', 'website', 'undertaking', 'accuracy', 'completeness', 'None', 'affiliate', 'representatives', 'liability', 'negligence', 'loss', 'contents', 'connection', 'Sandro', 'Maje', 'Fursac', '47 countries', 'network', '1,600 stores', 'ticker', 'CONTACTS', 'brunswickgroup', '6.', '2024']",2024-01-26,2024-01-27,marketscreener.com
35483,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/01/26/2817614/0/en/BGHL-GBP-NAV-s.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 25 Jan 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.6547 ¬£ 24.6884 Estimated MTD return 0.39 % 0.48 % Estimated YTD return 0.39 % 0.48 % Estimated ITD return 176.55 % 146.88 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 25.40 N/A Premium/discount to estimated NAV -8.15 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 150.00 Premium/discount to estimated NAV N/A -12.91 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.1104 Class GBP A Shares (estimated) ¬£ 132.3625The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.0,negative,0.01,0.27,0.72,True,English,"['BGHL', 'GBP', 'NAV', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'Euro Shares Amsterdam', 'US Investment Company Act', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-01-26,2024-01-27,globenewswire.com
35484,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/01/26/2817615/0/en/BGHL-EUR-NAV-s.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED   Ordinary Shares  The Directors of Boussard & Gavaudan Holding...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 25 Jan 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.6547 ¬£ 24.6884 Estimated MTD return 0.39 % 0.48 % Estimated YTD return 0.39 % 0.48 % Estimated ITD return 176.55 % 146.88 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 25.40 N/A Premium/discount to estimated NAV -8.15 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 150.00 Premium/discount to estimated NAV N/A -12.91 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.1104 Class GBP A Shares (estimated) ¬£ 132.3625The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.0,negative,0.01,0.27,0.72,True,English,"['BGHL', 'EUR', 'NAV', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'Euro Shares Amsterdam', 'US Investment Company Act', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-01-26,2024-01-27,globenewswire.com
35485,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-36044/news/BGHL-EUR-NAV-s-45818465/,BGHL (EUR): NAV(s) -January 26  2024 at 01:31 am EST,(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-36044/news/BG‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 25 Jan 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.6547 ¬£ 24.6884 Estimated MTD return 0.39 % 0.48 % Estimated YTD return 0.39 % 0.48 % Estimated ITD return 176.55 % 146.88 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 25.40 N/A Premium/discount to estimated NAV -8.15 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 150.00 Premium/discount to estimated NAV N/A -12.91 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.1104 Class GBP A Shares (estimated) ¬£ 132.3625The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.01,0.99,0.01,negative,0.01,0.27,0.72,True,English,"['BGHL', 'EUR', 'January', '01', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'Euro Shares Amsterdam', 'US Investment Company Act', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-01-26,2024-01-27,marketscreener.com
35486,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-3840782/news/BGHL-GBP-NAV-s-45818466/,BGHL (GBP): NAV(s) -January 26  2024 at 01:31 am EST,(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-3840782/news/BGHL-GBP-NA‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 25 Jan 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.6547 ¬£ 24.6884 Estimated MTD return 0.39 % 0.48 % Estimated YTD return 0.39 % 0.48 % Estimated ITD return 176.55 % 146.88 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 25.40 N/A Premium/discount to estimated NAV -8.15 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 150.00 Premium/discount to estimated NAV N/A -12.91 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.1104 Class GBP A Shares (estimated) ¬£ 132.3625The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.01,0.98,0.01,negative,0.01,0.27,0.72,True,English,"['BGHL', 'GBP', 'January', '01', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'Euro Shares Amsterdam', 'US Investment Company Act', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-01-26,2024-01-27,marketscreener.com
35487,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SIGNIFY-N-V-27862555/news/Signify-reports-full-year-sales-of-EUR-6-7-billion-operational-profitability-of-10-0-and-a-free-ca-45818364/,Signify reports full-year sales of EUR 6.7 billion  operational profitability of 10.0% and a free cash flow of 8.7% of sales,(marketscreener.com) Press Release January 26  2024 Signify reports full-year sales of EUR 6.7 billion  operational profitability of 10.0% and a free cash flow of 8.7% of sales Full year 20231 Signify's installed base of connected light points increased from ‚Ä¶,Press ReleaseJanuary 26  2024Signify reports full-year sales of EUR 6.7 billion  operational profitability of 10.0% and a free cash flow of 8.7% of salesFull year 20231Signify's installed base of connected light points increased from 114 million at YE 22 to 124 million at YE 23On track for three Brighter Lives  Better World 2025 sustainability program commitmentsSales of EUR 6 704 million; nominal sales decline of -10.8% and CSG of -8.3%LED-based sales represented 85% of total sales (FY 22: 83%)Adj. EBITA margin of 10.0% (FY 22: 10.1%)Net income of EUR 215 million (FY 22: EUR 532 million incl. one-time effects of EUR 184 million)Free cash flow of EUR 586 million (FY 22: EUR 445 million)  representing 8.7% of salesFourth quarter 2023Sales of EUR 1 734 million; nominal sales decline of -12.3% and CSG of -7.7%Adj. EBITA margin of 12.1% (Q4 22: 10.2%)Net income of EUR 59 million (Q4 22: EUR 86 million)Free cash flow of EUR 295 million (Q4 22: EUR 364 million)DividendProposal to increase its cash dividend to EUR 1.55 per share over 2023 (FY 22: EUR 1.50)Eindhoven  the Netherlands ‚Äì Signify (Euronext: LIGHT)  the world leader in lighting  today announced the company‚Äôs fourth quarter and full-year 2023 results.‚ÄúIn Q4  our gross margin was again strong  confirming our improving operational performance. This brought our adjusted EBITA margin into double digits for the full year. While we continued to face adverse market conditions in some geographies and in the consumer and OEM segments  we have gained share with our professional connected systems. We over-delivered against our free cash flow guidance  with close to EUR 600m in cash  representing 8.7% of sales. We are also proud to have surpassed the circular revenues sustainability target two years ahead of schedule. I would like to thank our employees and partners for their continued hard work and dedication to help us achieve these results ‚Äù said Eric Rondolat  CEO of Signify.‚ÄúWhile we anticipate challenging conditions will persist through the year ahead  I am confident in our strategy and in our proven ability to adapt. In the past quarter  we introduced a new operating model and measures that will enhance our performance and deliver annualized savings in excess of EUR 200 million. We will continue to protect our gross margin and enhance our focus on costs. We have developed strategic advantages that will help us to gain share and improve profitability while generating a strong free cash flow in 2024.‚ÄùBrighter Lives  Better World 2025Signify completed the third year of its Brighter Lives  Better World 2025 sustainability program   making continued progress towards doubling its positive impact on the environment and society by the end of 2025. Signify is on track to deliver on three of its sustainability program commitments:Double the pace of the Paris agreementSignify is on track to reduce emissions across the entire value chain by 40% against the 2019 baseline - double the pace required by the Paris Agreement. This is driven by Signify's leadership in energy efficient and connected LED lighting solutions  which significantly reduce emissions during the use phase.Double Circular revenuesCircular revenues increased to 33%  up 1% over the third quarter  surpassing the 2025 target of 32%. The main contribution was from serviceable luminaires  with a strong performance from both consumer and professional.Double Brighter lives revenuesBrighter lives revenues remained at 31%  on track to reach the 2025 target of 32%. This includes a strong contribution from professional luminaires that support the well-being of wildlife.Double the percentage of women in leadershipThe percentage of women in leadership positions remained at 29%  slightly off track versus the 2023 target. Signify continues its actions to increase representation through focused hiring practices for diversity across all levels  and through retention and engagement actions to reduce attrition.In the fourth quarter  Signify received several external recognitions for its leadership in Sustainability. Signify was included in the DJSI World Index for the 7th consecutive year  was included in the DJSI Europe Index for the 6th time  and achieved the EcoVadis Platinum rating for the 4th consecutive year.OutlookFor 2024  Signify expects:An Adjusted EBITA margin improvement of up to 50 bps  including first benefits from the announced restructuring programFree cash flow generation of 6-7% of sales  including an incremental and non-recurring negative impact of around EUR 150 million related to the restructuring program and a reduction of US pension liabilitiesCapital allocationSignify proposes a cash dividend of EUR 1.55 per share for 2023  in line with its policy to pay an increasing annual cash dividend per share year on year. The dividend proposal is subject to approval at the Annual General Meeting of Shareholders (AGM) to be held on May 14  2024. Further details will be provided in the agenda for the AGM.In line with its aim to maintain a robust capital structure and an investment grade credit rating  Signify expects to further deleverage its gross debt and reduce its US pension liabilities in 2024.Signify will continue to invest in organic and inorganic growth opportunities in line with its strategic priorities.Conference call and audio webcastEric Rondolat (CEO) and Javier van Engelen (CFO) will host a conference call for analysts and institutional investors at 9:00 a.m. CET to discuss the fourth quarter and full year 2023 results. A live audio webcast of the conference call will be available via the Investor Relations WebsiteThe analyst presentation is available via this link1This press release contains certain non-IFRS financial measures and ratios  such as comparable sales growth  EBITA  adjusted EBITA and free cash flow  and related ratios  which are not recognized measures of financial performance or liquidity under IFRS. For a reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures  see appendix B  Reconciliation of non-IFRS financial measures  of this press release.Attachment,neutral,0.18,0.8,0.02,mixed,0.64,0.25,0.11,True,English,"['free cash flow', 'operational profitability', 'full-year sales', 'Signify', 'Brighter Lives, Better World 2025 sustainability program', 'Better World 2025 sustainability program commitments', 'free cash flow guidance', 'Free cash flow generation', 'connected LED lighting solutions', 'Adjusted EBITA margin improvement', 'increasing annual cash dividend', 'strong free cash flow', 'three Brighter Lives', 'DJSI World Index', 'Annual General Meeting', 'Double Brighter lives', 'Brighter lives revenues', 'new operating model', 'entire value chain', 'several external recognitions', 'DJSI Europe Index', 'EcoVadis Platinum rating', 'US pension liabilities', 'Adj. EBITA margin', 'circular revenues sustainability', 'adverse market conditions', 'non-recurring negative impact', 'connected light points', 'professional connected systems', '7th consecutive year', '4th consecutive year', 'Double Circular revenues', 'nominal sales decline', 'improving operational performance', 'world leader', 'restructuring program', 'gross margin', 'double digits', 'strong performance', 'strong contribution', 'challenging conditions', 'positive impact', 'Press Release', 'operational profitability', 'installed base', 'Net income', 'one-time effects', 'Fourth quarter', 'OEM segments', 'hard work', 'Eric Rondolat', 'past quarter', 'annualized savings', 'strategic advantages', 'Paris agreement', 'energy efficient', 'use phase', 'third quarter', 'main contribution', 'serviceable luminaires', 'professional luminaires', 'hiring practices', '6th time', 'first benefits', 'Capital allocation', 'Further details', 'Full year', 'third year', 'dividend proposal', 'full-year sales', 'LED-based sales', 'total sales', 'full-year 2023 results', 'engagement actions', 'leadership positions', 'January', 'Signify', 'track', 'CSG', 'share', 'Eindhoven', 'Netherlands', 'Euronext', 'company', 'geographies', 'consumer', 'schedule', 'employees', 'partners', 'dedication', 'CEO', 'strategy', 'proven', 'measures', 'excess', 'focus', 'costs', 'progress', 'environment', 'society', 'pace', 'emissions', '2019 baseline', '2025 target', 'well-being', 'wildlife', 'percentage', 'women', '2023 target', 'representation', 'diversity', 'levels', 'retention', 'attrition', 'Outlook', '50 bps', 'incremental', 'reduction', 'policy', 'approval', 'AGM', 'May', 'agenda', 'aim', 'robus', '2024']",2024-01-26,2024-01-27,marketscreener.com
35488,EuroNext,NewsApi.org,https://www.etfdailynews.com/2024/01/26/public-storage-nysepsa-given-consensus-recommendation-of-moderate-buy-by-brokerages/,Public Storage (NYSE:PSA) Given Consensus Recommendation of ‚ÄúModerate Buy‚Äù by Brokerages,Shares of Public Storage (NYSE:PSA ‚Äì Get Free Report) have been assigned an average recommendation of ‚ÄúModerate Buy‚Äù from the seven research firms that are covering the firm  Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommen‚Ä¶,Shares of Public Storage (NYSE:PSA ‚Äì Get Free Report) have been assigned an average recommendation of ‚ÄúModerate Buy‚Äù from the seven research firms that are covering the firm  Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $302.86.Several equities analysts recently commented on PSA shares. Truist Financial increased their price objective on shares of Public Storage from $285.00 to $315.00 and gave the company a ‚Äúbuy‚Äù rating in a research note on Thursday  December 28th. Wells Fargo & Company cut shares of Public Storage from an ‚Äúoverweight‚Äù rating to an ‚Äúequal weight‚Äù rating and upped their price target for the company from $270.00 to $280.00 in a research report on Tuesday  December 12th. The Goldman Sachs Group upped their price target on shares of Public Storage from $307.00 to $340.00 and gave the company a ‚Äúbuy‚Äù rating in a research report on Thursday  January 11th. StockNews.com began coverage on shares of Public Storage in a research report on Saturday  October 21st. They issued a ‚Äúhold‚Äù rating for the company. Finally  Evercore ISI upped their price target on shares of Public Storage from $268.00 to $271.00 and gave the company an ‚Äúin-line‚Äù rating in a research report on Monday  November 27th.Get Public Storage alerts:View Our Latest Analysis on PSAPublic Storage Stock PerformanceShares of Public Storage stock opened at $291.68 on Friday. The company has a 50 day moving average of $284.42 and a 200-day moving average of $275.49. Public Storage has a 1-year low of $233.18 and a 1-year high of $316.48. The company has a current ratio of 0.98  a quick ratio of 0.98 and a debt-to-equity ratio of 1.54. The company has a market cap of $51.29 billion  a PE ratio of 26.74  a price-to-earnings-growth ratio of 4.01 and a beta of 0.55.Public Storage (NYSE:PSA ‚Äì Get Free Report) last issued its quarterly earnings data on Monday  October 30th. The real estate investment trust reported $3.20 EPS for the quarter  missing the consensus estimate of $4.21 by ($1.01). The company had revenue of $1.14 billion during the quarter  compared to the consensus estimate of $1.14 billion. Public Storage had a net margin of 45.46% and a return on equity of 34.76%. Public Storage‚Äôs revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year  the company earned $4.13 EPS. As a group  equities research analysts forecast that Public Storage will post 16.82 earnings per share for the current fiscal year.Public Storage Announces DividendThe company also recently disclosed a quarterly dividend  which was paid on Thursday  December 28th. Stockholders of record on Wednesday  December 13th were given a dividend of $3.00 per share. This represents a $12.00 annualized dividend and a dividend yield of 4.11%. The ex-dividend date of this dividend was Tuesday  December 12th. Public Storage‚Äôs dividend payout ratio (DPR) is presently 109.99%.Insider Transactions at Public StorageIn other Public Storage news  Director John Reyes sold 50 000 shares of the firm‚Äôs stock in a transaction on Monday  December 11th. The shares were sold at an average price of $275.98  for a total value of $13 799 000.00. Following the completion of the sale  the director now directly owns 174 192 shares in the company  valued at $48 073 508.16. The transaction was disclosed in a filing with the Securities & Exchange Commission  which is available at the SEC website. In other Public Storage news  insider Nathaniel A. Vitan sold 265 shares of the firm‚Äôs stock in a transaction on Wednesday  December 13th. The shares were sold at an average price of $282.17  for a total value of $74 775.05. Following the transaction  the insider now directly owns 13 021 shares of the company‚Äôs stock  valued at $3 674 135.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission  which can be accessed through this link. Also  Director John Reyes sold 50 000 shares of the firm‚Äôs stock in a transaction on Monday  December 11th. The shares were sold at an average price of $275.98  for a total transaction of $13 799 000.00. Following the completion of the transaction  the director now directly owns 174 192 shares in the company  valued at $48 073 508.16. The disclosure for this sale can be found here. Insiders sold a total of 55 665 shares of company stock worth $15 268 673 over the last three months. 11.00% of the stock is owned by company insiders.Institutional Inflows and OutflowsLarge investors have recently made changes to their positions in the business. Sunbelt Securities Inc. bought a new position in shares of Public Storage during the first quarter valued at about $26 000. Focused Wealth Management Inc purchased a new position in shares of Public Storage in the second quarter worth about $29 000. ICA Group Wealth Management LLC purchased a new position in shares of Public Storage in the fourth quarter worth about $29 000. Glass Jacobson Investment Advisors llc purchased a new position in shares of Public Storage in the second quarter worth about $34 000. Finally  Private Ocean LLC increased its stake in shares of Public Storage by 5 450.0% in the fourth quarter. Private Ocean LLC now owns 111 shares of the real estate investment trust‚Äôs stock worth $34 000 after purchasing an additional 109 shares in the last quarter. 78.75% of the stock is owned by institutional investors.About Public Storage(Get Free ReportPublic Storage  a member of the S&P 500 and FT Global 500  is a REIT that primarily acquires  develops  owns  and operates self-storage facilities. At September 30  2023  we had: (i) interests in 3 028 self-storage facilities located in 40 states with approximately 217 million net rentable square feet in the United States and (ii) a 35% common equity interest in Shurgard Self Storage Limited (Euronext Brussels: SHUR)  which owned 267 self-storage facilities located in seven Western European nations with approximately 15 million net rentable square feet operated under the Shurgard brand.Recommended StoriesReceive News & Ratings for Public Storage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Public Storage and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.04,0.95,0.01,negative,0.01,0.41,0.58,True,English,"['Public Storage', 'Consensus Recommendation', 'Moderate Buy', 'NYSE', 'PSA', 'Brokerages', 'ICA Group Wealth Management LLC', 'Focused Wealth Management Inc', 'real estate investment trust', 'The Goldman Sachs Group', 'insider Nathaniel A. Vitan', 'other Public Storage news', 'Public Storage Stock Performance Shares', 'average twelve-month price target', 'Marketbeat Ratings reports', 'Several equities analysts', '50 day moving average', '200-day moving average', 'seven research firms', 'Sunbelt Securities Inc.', 'Get Free Report', 'equal weight‚Äù rating', 'Director John Reyes', 'last three months', 'equities research analysts', 'Public Storage alerts', 'Public Storage Announces', 'quarterly earnings data', 'current fiscal year', 'dividend payout ratio', 'Three analysts', 'average price', 'current ratio', 'average recommendation', 'last year', 'research report', 'Insider Transactions', 'research note', 'price objective', 'quarterly dividend', 'quick ratio', 'PE ratio', 'earnings-growth ratio', 'Moderate Buy', 'hold recommendation', 'buy recommendation', 'Truist Financial', 'buy‚Äù rating', 'Wells Fargo', 'overweight‚Äù rating', 'StockNews.com', 'hold‚Äù rating', 'Evercore ISI', 'November 27th', 'Latest Analysis', '1-year low', '1-year high', 'market cap', 'consensus estimate', 'net margin', 'year basis', 'same period', 'previous year', 'ex-dividend date', 'Exchange Commission', 'SEC website', 'Institutional Inflows', 'Large investors', 'new position', 'total value', '$12.00 annualized dividend', 'dividend yield', 'equity ratio', 'legal filing', 'first quarter', 'second quarter', 'December 28th', 'NYSE:PSA', 'total transaction', 'company stock', 'PSA shares', 'company insiders', '16.82 earnings', '50,000 shares', '174,192 shares', '265 shares', '13,021 shares', '55,665 shares', 'brokers', 'Thursday', 'Tuesday', 'January', 'coverage', 'Saturday', 'October', 'line', 'Monday', 'Friday', 'debt', 'beta', 'revenue', 'return', 'Stockholders', 'record', 'Wednesday', 'DPR', 'completion', 'sale', 'link', 'disclosure', 'Outflows', 'changes', 'positions', 'business', 'fou', '45.']",2024-01-26,2024-01-27,etfdailynews.com
35489,EuroNext,NewsApi.org,https://www.irishtimes.com/business/2024/01/26/markets-wrap/,European shares advance as investors mull interest rate-cut prospects,European shares rose on Friday as investors assessed interest rate cut prospects following the European Central Bank‚Äôs latest policy decision.,In the United States  Intel slumped more than 11% to a six-week low after forecasting that its first-quarter revenue could miss estimates by more than $2bn. Photograph: Getty ImagesEuropean shares rose on Friday as investors assessed interest rate cut prospects following the European Central Bank‚Äôs latest policy decision.DublinThe Euronext Dublin rose slightly  buoyed by travel and food stocks to end the week 0.37 per cent higher at 9 066.84.Banking shares were mixed on the day  with Bank of Ireland gaining 1.5 per cent before the closing bell  and Permanent TSB adding 0.3 per cent  while AIB saw its shares dip 0.25 per cent.In travel stocks  Ryanair ended the day at ‚Ç¨18.80  a gain of 0.35 per cent  while ferries group Irish Continental was 0.65 per cent higher. Dalata Hotel Group saw its shares gain almost 1.7 per cent  ending the week at ‚Ç¨4.83.READ MORE‚ÄòTo blame the lowest paid for challenges in our economy is cheap‚Äô Listen | 52:56Shares in Glanbia rose 1.67 per cent to ‚Ç¨15.80  while Kerry Group was 1.07 per cent higher.LondonBritain‚Äôs FTSE 100 clocked its biggest percentage gain since last October  as upbeat earnings from European luxury firms boosted shares of Burberry and Diageo  while investors took comfort from data that showed UK consumer sentiment hit a two-year high.The FTSE 100 climbed 1.4 per cent on Friday to log its first weekly gain of the year and the biggest in more than four months. The midcap FTSE 250 index also rose 0.6 per cent  marking its biggest weekly gain in six weeks.British luxury retailer Burberry climbed 4.9 per cent  after French luxury giant LVMH reported a 10 per cent rise in fourth-quarter sales  reassuring investors about the sector‚Äôs resilience to economic headwinds  particularly in China.Vodafone shares advanced 3.9 per cent after the British government approved the telecom operator‚Äôs strategic relationship agreement with Abu Dhabi-based telecoms group e&.Shares in Superdry lost 2.6 per cent after the fashion retailer said it did not expect market conditions to improve in the near term following a tough Christmas season  also adding that finance chief Shaun Wills would step down at the end of March.EuropeThe pan-European STOXX 600 index ended 1.1 per cent higher  hitting its highest level in two years and clocking a weekly advance of 3.1 per cent.LVMH jumped 12.8 per cent after the world‚Äôs largest luxury group posted a 10 per cent rise in fourth-quarter sales  driven by resilient demand  including from Chinese buyers.Remy Cointreau advanced 15.2 per cent after the French spirits maker posted a slightly smaller-than-expected decline in third-quarter sales. Rivals Pernod Ricard and Diageo also added 7.9 per cent and 5.1 per cent  respectively.France‚Äôs CAC 40 index  which houses both stocks  rallied 2.3 per cent and outperformed other regional bourses.New YorkThe benchmark S&P 500 scaled another record high on Friday after an in-line inflation print signalling continued moderation in price pressures provided some relief.Dragging down the Nasdaq  Intel slumped 11.1 per cent to a six-week low after forecasting that its first-quarter revenue could miss estimates by over $2 billion.With other chip stocks Broadcom  Qualcomm and Micron Technology losing over 1 per cent each  the Philadelphia SE Semiconductor index shed 2.3 per cent.The S&P 500 technology sector led sectoral losses with a 0.6 per cent decline.Chipmaking tools maker KLA Corp also shed 5.9 per cent following its third-quarter revenue forecast below estimates.At 11.41am in the US  the Dow Jones Industrial Average was up 95.80 points  or 0.25 per cent  at 38 144.93  the S&P 500 was up 2.93 points  or 0.06 per cent  at 4 897.09  and the Nasdaq Composite was down 12.62 points  or 0.08 per cent  at 15 497.87.Among others  American Express jumped 7.6 per cent  hitting a record high  as the credit card firm forecast a higher-than-expected annual profit  while peer Visa declined 1.6 per cent after the world‚Äôs largest payments processor‚Äôs tepid current-quarter revenue growth forecast.Colgate-Palmolive rose 2.3 per cent after the toothpaste maker posted upbeat fourth-quarter results. ‚Äî Additional reporting: Reuters,neutral,0.03,0.96,0.01,mixed,0.34,0.22,0.44,True,English,"['interest rate-cut prospects', 'European shares', 'investors', 'tepid current-quarter revenue growth forecast', 'interest rate cut prospects', 'finance chief Shaun Wills', 'line inflation print signalling', 'Dow Jones Industrial Average', 'The S&P 500 technology sector', 'Philadelphia SE Semiconductor index', 'Abu Dhabi-based telecoms group', 'benchmark S&P 500', 'third-quarter revenue forecast', 'latest policy decision', 'UK consumer sentiment', 'French luxury giant', 'strategic relationship agreement', 'tough Christmas season', 'pan-European STOXX 600 index', 'other regional bourses', 'credit card firm', 'largest payments processor', 'Dalata Hotel Group', 'largest luxury group', 'European luxury firms', 'French spirits maker', 'Chipmaking tools maker', 'biggest percentage gain', 'first weekly gain', 'biggest weekly gain', 'midcap FTSE 250 index', 'British luxury retailer', 'other chip stocks', 'upbeat fourth-quarter results', 'The Euronext Dublin', 'European Central Bank', '10 per cent rise', '0.6 per cent decline', 'Micron Technology', 'first-quarter revenue', 'CAC 40 index', 'ferries group', 'Kerry Group', 'The FTSE 100', 'weekly advance', 'toothpaste maker', 'upbeat earnings', 'British government', 'fashion retailer', 'third-quarter sales', '0.35 per cent', '3.1 per cent', '7.9 per cent', '5.1 per cent', 'fourth-quarter sales', 'European shares', 'United States', 'Getty Images', 'food stocks', 'closing bell', 'Permanent TSB', 'Irish Continental', 'last October', 'four months', 'six weeks', 'economic headwinds', 'telecom operator', 'market conditions', 'near term', 'highest level', 'two years', 'resilient demand', 'Chinese buyers', 'Remy Cointreau', 'Pernod Ricard', 'New York', 'continued moderation', 'price pressures', 'sectoral losses', 'KLA Corp', 'American Express', 'annual profit', 'peer Visa', 'Additional reporting', 'six-week low', 'travel stocks', 'Nasdaq Composite', 'Banking shares', 'Vodafone shares', '1.5 per', '0.3 per', '2.3 per', 'Intel', 'estimates', 'Photograph', 'Friday', 'investors', 'Ireland', 'AIB', 'Ryanair', 'READ', 'challenges', 'economy', 'Glanbia', 'London', 'Britain', 'Burberry', 'Diageo', 'comfort', 'data', 'LVMH', 'resilience', 'China', 'Superdry', 'end', 'March', 'world', 'Rivals', 'France', 'record', 'relief', 'Broadcom', 'Qualcomm', '11.41am', 'others', 'expected', 'Colgate-Palmolive', 'Reuters', '1.7', '95.80', '0.25', '0.06', '0.08']",2024-01-26,2024-01-27,irishtimes.com
35490,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SARTORIUS-STEDIM-BIOTECH-27471609/news/Sartorius-Stedim-Biotech-publishes-preliminary-unaudited-results-for-fiscal-2023-and-provides-2024-45818380/,Sartorius Stedim Biotech publishes preliminary  unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook,(marketscreener.com) Sartorius Stedim Biotech SA / Key word: Annual Results/Preliminary ResultsSartorius Stedim Biotech publishes preliminary  unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook 2‚Ä¶,Sartorius Stedim Biotech SA / Key word(s): Annual Results/Preliminary ResultsSartorius Stedim Biotech publishes preliminary  unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook26-Jan-2024 / 07:00 CET/CESTAubagne  January 26  2024Sartorius Stedim Biotech publishes preliminary  unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlookPreliminary  unaudited 2023 results in line with forecast 1 : sales revenue of 2 775 million euros  in constant currencies 2 ‚Äì20.7 percent organically 2 and -18.7 percent including acquisitions 3 (reporte d: -20.5 percent )Underlying EBITDA 2 at 785 million euros  resulting margin at 28.3 percent; net profit 2 at 310 million eurosDemand recovery since end of third quarter: fourth quarter order intake slightly higher than sales revenue2024 outlook: Group aims to achieve sales revenue growth in the mid to high single-digit percentage range with an underlying profit margin of more than 30 percentRapid reduction of leverage through strong operating cash flow planned ; acceleration through additional equity measures remains an optionInvestment program focused on innovation  customer proximity  resilience  and sustainability in executionMedium-term ambition through to 2028: average annual increase in sales revenue in the low- to mid-teens percentage range  profit margin to increase to above 35 percent by 2028Uncertainties remain high due to the global political and economic situationSartorius Stedim Biotech  a leading partner of the biopharma industry  expects a return to profitable growth in 2024 and a dynamic business development for the five-year period through to 2028. In 2023  soft demand  which lasted longer than expected post-pandemic  led to a temporary decline in sales revenue and earnings across the entire life science sector.‚Äú2023 was a year of transition in our industry. Destocking  relatively low production levels and muted investment activity at customers weighed on our business development and led to a decline in sales revenue. At the same time and supported by cost measures  our profitability remained at a healthy and above pre-pandemic level. As many customers are further advanced in optimizing their inventory levels  we have seen business picking up since the end of the third quarter and expect this trend to gradually gain traction over the course of the current year ‚Äù said Ren√© F√°ber  CEO of Sartorius Stedim Biotech.‚ÄúStrategically  the acquisition of transfection reagent specialist Polyplus and the respective expansion of our technology platform for cell and gene therapy applications were major milestones for our company in 2023. The portfolio will enable us to significantly contribute to our customers‚Äô efforts to bring these highly innovative therapies to the market and to patients faster ‚Äú continued F√°ber.Business development2In 2023  the ongoing demand normalization following the pandemic and a longer-than-expected reduction in inventories among customers led to subdued results and numerous forecast adjustments across the life science industry. Accordingly  sales revenue for Sartorius Stedim Biotech decreased compared to the previous year‚Äôs high base  which had been characterized by Covid19-related positive extraordinary effects. The company recorded consolidated sales revenue of 2 775 million euros in 2023  which corresponds to a decline of 18.7 percent in constant currencies (guidance: around -19 percent; organic: -20.7 percent; reported: - 20.5 percent). This includes a growth contribution from acquisitions3 of around 2 percentage points. Excluding the pandemic-related business  the decline in constant currencies was around 14 percent. Main drivers of the soft development were customer destocking which began after the end of the pandemic and is taking longer than expected  in some cases due to relatively low production levels   the largely discontinued business with Russian customers  and an overall muted investment activity on the part of customers  primarily in China and the USA.As expected  the general market weakness affected all business regions. In the EMEA 4 region  which accounted for around 39 percent of total Group revenue  sales revenue declined by 16.7 percent compared to the previous year  which was particularly influenced by business with vaccine manufacturers. In addition  growth was dampened by the discontinuation of business with Russian customers . Sales revenue in the Americas region was down 15.5 percent against the backdrop of inventory reductions and low investment activity by customers in the USA. This corresponds to a share of around 38 percent of total Group revenue. The investment slowdown was even more pronounced in China  leading to a significant decline of 26.4 percent in sales revenue in the Asia | Pacific region  which accounted for around 23 percent of total Group sales revenue.The temporarily weaker market environment was even more significantly reflected in order intake  which decreased by 23.6 percent in constant currencies (reported: -25.3 percent) to 2.476 million euros. In line with progress made by customers in reducing their inventories  business began to recover at the end of the third quarter  so that order intake was slightly above sales revenue in the fourth quarter.The Group‚Äôs underlying EBITDA decreased by 35.7 percent to 785 million euros due to the volume development and product mix effects. The resulting margin was 28.3 percent ( guidance: slightly above 28 percent; prior-year period: 35.0 percent). Price effects on the procurement and customer side largely offset each other.Underlying net profit totaled 386 million euros  compared with 797 million euros in the prior-year period while net profit amounted to 310 million euros  compared with 876 million euros in 2022. Underlying earnings per share were 4.19 euros (prior-year period: 8.64 euros) and earnings per share were 3.36 (prior-year period: 9.51 euros).Sartorius Stedim Biotech employed 10 662 people group wide as of December 31  2023  compared to 11 934 at the end of the prior year. The reduction resulted primarily from the expiry of fixed-term employment contracts and regular attrition.Key financial indicatorsEquity was 2 673 million euros as of December 31  2023. Following the Polyplus acquisition  the equity ratio2 stood in line with expectations at 34.5 percent (December 31  2022: 2 514 million euros and 49.6 percent  respectively ). Gross debt was 3 682 million euros (December 31  2022: 1 136 million euros)  while net debt stood at 3 565 million euros  resulting in a ratio of net debt to underlying EBITDA2 of 4.5 (December 31  2022: 1 029 million euros and 0.8  respectively). Net operating cash flow stood at 746 million euros  compared with 612 million euros in the prior-year period. Despite the decline in earnings  the increase was primarily achieved through the optimization of working capital  as planned. While Sartorius Stedim Biotech had systematically increased inventories in 2022 and previous years to secure supply ability in view of temporarily constrained supply chains  inventory reductions started as planned in 2023 . The ratio of capital expenditures (capex) to sales revenue was 17.1 percent (prior-year period: 12.3 percent).Outlook for fiscal 2024Based on the slight demand recovery since the end of the third quarter of 2023 and the market outlook forecast by industry observers  Sartorius Stedim Biotech expects profitable growth for 2024 and beyond. However  as inventory optimization measures of customers have not yet been fully completed the company projects business momentum to increase only gradually over the course of the year leading to a moderate first half of 2024. In addition  business performance could also be affected by increasing geopolitical tensions going forward.Against this backdrop of still somewhat unstable market trends and therefore limited visibility   management forecasts an increase in Group sales revenue in the mid to high single-digit percentage range  including a contribution of acquired businesses of around 2 percentage points. In terms of profitability  management expects the underlying EBITDA margin to rise to more than 30 percent compared to the previous year‚Äôs figure of 28.3 percent. The above-average profitability of the Polyplus business will have a slightly positive effect on the margin development. The capex ratio is projected to be around 13 percent  below the prior-year figure of 17.1 percent. Excluding potential capital measures and/or acquisitions the ratio of net debt to underlying EBITDA2 is expected to be 3.5.‚ÄúBeyond focusing on customer satisfaction  innovation  and organic growth  we will fully concentrate on further efficiency gains and strong cash generation in 2024 to rapidly run down the debt leverage which is at an elevated level following the Polyplus acquisition. To deleverage even faster while maintaining strategic flexibility we are also continuing to consider potential equity measures  subject to market conditions  for example targeting a leverage reduction by approximately one turn  ‚Äù said F√°ber.Medium-term outlook until 2028Sartorius Stedim Biotech intends to continue its profitable growth course in the long term and expects to grow faster than the market. According to the new medium-term targets  the Group plans to achieve average annual growth in the low- to mid-teens percentage range over the five-year period to 2028 of which acquisitions are anticipated to contribute around a fifth. The underlying EBITDA margin is also expected to increase and reach above 35 percent in 2028. The margin target includes expenses of around 1 percent of Group sales revenue for measures to reduce the company‚Äôs CO 2 emission intensity.‚Äú Our goals remain ambitious as we anticipate ever-increasing demand for biopharmaceuticals and vaccines due to a growing and aging population  improved access to medicines in emerging markets  as well as rapidly expanding markets for biosimilars and cell and gene therapies. At the same time  there is a need for continuous innovation  not only to help bring the promises of new therapies to life  but to also support our customers‚Äô sustainability efforts. With our broad portfolio we see ourselves excellently positioned to support our customers in their endeavors and to continue to outgrow the market  ‚Äú commented F√°ber.Forecasts have been prepared based on historical information and are consistent with accounting policies. All forecast figures are based on constant currencies  as in the past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition  uncertainties due to the changed geopolitical situation  such as the emerging decoupling tendencies of various countries  are playing a greater role. This results in higher uncertainty when forecasting business figures.1 Current forecast for 2023 from October 20232 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.Constant currencies: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous periodOrganic: Organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidationOrder intake: All customer orders contractually concluded and booked during the respective reporting periodUnderlying EBITDA: Earnings before interest  taxes  depreciation  and amortization and adjusted for extraordinary itemsUnderlying net profit: Profit for the period after non-controlling interest  adjusted for extraordinary items and amortization  as well as based on the normalized financial result and the normalized tax rateEquity ratio: Equity in relation to the balance sheet totalRatio of net debt to underlying EBITDA: Quotient of net debt and underlying EBITDA over the past 12 months  including the pro forma amount contributed by acquisitions for this periodNet profit after non-controlling interest3 Acquisitions of Polyplus  the Novasep chromatography division and Albumedix4 EMEA = Europe  Middle East  AfricaThis press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks  uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.Conference callRen√© F√°ber  CEO of the Sartorius Stedim Biotech Group  will discuss the company‚Äôs business results with analysts and investors in a conference call at 1.00 p.m. CEST on January 26  2024. Please click on the link to register: https://media.choruscall.eu/mediaframe/webcast.html?webcastid=4Ajj7aeDFurther information and media contentwww.sartorius.com/newsroomFinancial calendarMarch 26  2024 Annual General MeetingApril 18  2024 Publication of the quarterly figures January to March 2024July 19  2024 Publication of the half-year figures January to June 2024October 17  2024 Publication of the nine-month figures January to September 2024Preliminary key figures for the full year 2023in millions of ‚Ç¨ unless otherwise specified 2023 2022 Œî in % Œî in % cc1 Order Intake and Sales Revenue Order intake¬≤ 2 476.1 3 314.8 -25.3 -23.6 Sales revenue 2 775.5 3 492.7 -20.5 -18.7 EMEA3 1 093.4 1 318.8 -17.1 -16.7 Americas3 1 054.0 1 277.8 -17.5 -15.5 Asia | Pacific3 628.1 896.2 -29.9 -26.4 Results EBITDA4 785.4 1 221.4 -35.7 EBITDA margin4 in % 28.3 35.0 -6.7pp Underlying net profit5 385.9 796.6 -51.6 Underlying earnings per share5 in ‚Ç¨ 4.19 8.64 -51 6 Net profit6 309.7 876.1 -64.6 Earnings per share‚Å∂ in ‚Ç¨ 3.36 9.51 -64.61 cc = constant currency: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period2 All customer orders contractually concluded and booked during the respective reporting period3 According to customer location4 Underlying EBITDA = earnings before interest  taxes  depreciation and amortization  and adjusted for extraordinary items5 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and amortization  as well as based on a normalized financial result and normalized tax rate6 After non-controlling interestReconciliation between EBIT and underlying EBITDAIn millions of ‚Ç¨unless otherwise specified 2023 2022 EBIT (operating result) 448.7 995.2 Extraordinary items 99.1 46.3 Depreciation and amortization 237.6 179.9 Underlying EBITDA 785.4 1 221.4In millions of ‚Ç¨ unless otherwise specified 2023 2022 EBIT (operating result) 448.7 995.2 Extraordinary items 99.1 46.3 Amortization | IFRS 3 91.1 60.7 Normalized financial result1 -114.1 -20.6 Normalized income tax (26%)2 -136.4 -281.2 Underlying net result after taxes 388.3 800.4 Non-controlling interest -2.4 -3.8 Underlying net result after taxes and non-controlling interest 385.9 796.6 Underlying earnings per share (in ‚Ç¨) 4.19 8.641 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability2 Normalized income tax based on the underlying profit before taxes and non-cash amortizationin millions of ‚Ç¨unless otherwise specified 2023 2022 Gross debt 3 681.8 1 135.7 - Cash & cash equivalents 116.6 107.1 Net debt 3 565.2 1 028.6 Underlying EBITDA (12 months) 785.4 1 221.4 + Pro forma EBITDA from acquisitions (12 months) 14.7 11.7 Pro forma underlying EBITDA (12 months) 800.0 1 233.1 Ratio of net debt to underlying EBITDA 4.5 0.8in millions of ‚Ç¨unless otherwise specified 2023 2022 Sales revenue 2 775.5 3 492.7 Capital expenditures 473.6 430.6 Capital expenditures as % of sales revenue 17.1 12.3A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions  the company based in Aubagne  France  helps its customers to manufacture biotech medications  such as cell and gene therapies  safely  rapidly  and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe  North America  and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023  the company generated sales revenue of around 2.8 billion euros  according to preliminary figures. Currently  more than 10 600 employees are working for customers around the globe.ContactPetra KirchhoffHead of Corporate Communications & Investor Relations+49 (0)551 308 1686petra.kirchhoff@sartorius.com,neutral,0.01,0.98,0.01,mixed,0.17,0.22,0.61,True,English,"['Sartorius Stedim Biotech', 'preliminary, unaudited results', 'new midterm outlook', 'fiscal 2023', '2024 guidance', 'low- to mid-teens percentage range', 'strong operating cash flow', 'Covid19-related positive extraordinary effects', 'high single-digit percentage range', 'entire life science sector', 'Sartorius Stedim Biotech SA', 'fourth quarter order intake', 'total Group sales revenue', 'transfection reagent specialist', 'gene therapy applications', 'life science industry', 'low production levels', 'additional equity measures', 'average annual increase', 'total Group revenue', 'option Investment program', 'new midterm outlook', 'ongoing demand normalization', 'general market weakness', 'weaker market environment', 'preliminary, unaudited results', 'Preliminary, unaudited 2023 results', 'Ren√© F√°ber', 'numerous forecast adjustments', 'low investment activity', 'underlying profit margin', 'dynamic business development', 'sales revenue growth', '2 percentage points', 'mid to', 'Preliminary Results', 'high base', 'Annual Results', 'third quarter', 'inventory levels', 'cost measures', 'investment slowdown', 'resulting margin', 'net profit', 'Demand recovery', 'soft demand', 'soft development', 'Key word', 'CEST Aubagne', 'constant currencies', 'Rapid reduction', 'customer proximity', 'Medium-term ambition', 'global political', 'economic situation', 'leading partner', 'biopharma industry', 'profitable growth', 'five-year period', 'same time', 'pre-pandemic level', 'respective expansion', 'technology platform', 'major milestones', 'innovative therapies', 'expected reduction', 'growth contribution', 'Main drivers', 'EMEA 4 region', 'vaccine manufacturers', 'Americas region', 'inventory reductions', 'Pacific region', '2,775 million euros', '785 million euros', 'current year', 'previous year', 'Business development2', 'pandemic-related business', 'business regions', 'many customers', 'customers‚Äô efforts', 'customer destocking', 'Russian customers', 'temporary decline', 'significant decline', '2024 outlook', '310 million', 'fiscal 2023', '2024 guidance', '07:00 CET', 'January', 'acquisitions', 'reporte', '20.5 percent', 'EBITDA', '28.3 percent', 'end', '30 percent', 'leverage', 'acceleration', 'innovation', 'resilience', 'sustainability', 'execution', '35 percent', 'Uncertainties', 'return', 'earnings', 'transition', 'profitability', 'healthy', 'traction', 'course', 'CEO', 'Polyplus', 'cell', 'company', 'portfolio', 'patients', 'inventories', 'consolidated', '18.7 percent', '20.7 percent', '14 percent', 'cases', 'overall', 'China', 'USA', '39 percent', '16.7 percent', 'discontinuation', 'backdrop', 'share', '38 percent', '26.4 percent', 'Asia', '23 percent', '23.6 percent']",2023-01-27,2024-01-27,marketscreener.com
35491,EuroNext,Bing API,https://www.brecorder.com/news/40286030,EU wheat futures fall,PARIS: Euronext wheat futures fell on Friday to near contract lows  pressured by a sharp drop in Chicago and worries about stiff export competition amid ample global supplies. March milling wheat on Paris-based Euronext was down 1.4% at 215.25 euros ($233. ...,PARIS: Euronext wheat futures fell on Friday to near contract lows  pressured by a sharp drop in Chicago and worries about stiff export competition amid ample globalsupplies. March milling wheat on Paris-based Euronext was down 1.4% at 215.25 euros ($233.78) a metric ton at 1554 GMT  near a life-of-contract low of 214 euros struck last week.A lull in demand this week  following a run of purchases by importers last week  has put the focus back on lagging European Union exports and cheaper competition from Black Sea supplies.‚ÄúAll the gains we saw this week have evaporated today  with Chicago back under $6 a bushel ‚Äù a French trader said.‚ÄúIt‚Äôs gone very quiet and there‚Äôs nothing to give the market impetus.‚ÄùEasing prices in Russia and rising volumes in Ukraine‚Äôs wartime sea shipping channel were keeping attention on competition from the Black Sea zone.‚ÄúRussian export prices for both 11.5% and 12.% protein wheat for February shipment are stillholding below $240 a ton FOB ‚Äù one German trader said.Traders said substantial numbers of grain ships previously booked to ship grains through the Red Sea were still sailing but it is becoming more difficult to book grain ships to make the Red Sea transit.‚ÄúWith more ships being diverted from the Red Sea because of the attacks  people are starting to ask whether Ukrainian wheat will find its way into markets like Algeria in greater volumes ‚Äù another trader said. Algeria is one of the largest export markets for EU wheat.Traders also noted news that the Chinese customs authorities have approved Argentine wheat for export to China  which could increase competition for French wheat in what has been a major export destination in recent years.,neutral,0.02,0.93,0.05,negative,0.02,0.22,0.76,True,English,"['EU wheat futures', 'lagging European Union exports', 'wartime sea shipping channel', 'ample global supplies', 'Chinese customs authorities', 'Black Sea supplies', 'Black Sea zone', 'major export destination', 'March milling wheat', 'Red Sea transit', 'Russian export prices', 'one German trader', 'Euronext wheat futures', 'largest export markets', 'stiff export competition', 'Paris-based Euronext', 'Easing prices', '12.% protein wheat', 'Ukrainian wheat', 'EU wheat', 'Argentine wheat', 'French wheat', 'contract lows', 'sharp drop', 'metric ton', 'French trader', 'market impetus', 'rising volumes', 'February shipment', 'ton FOB', 'substantial numbers', 'greater volumes', 'recent years', 'cheaper competition', 'grain ships', 'Friday', 'Chicago', 'worries', '215.25 euros', '1554 GMT', 'life', '214 euros', 'lull', 'demand', 'run', 'purchases', 'importers', 'focus', 'gains', 'bushel', 'Ukraine', 'attention', 'Traders', 'grains', 'attacks', 'people', 'way', 'Algeria', 'news', 'China']",2024-01-28,2024-01-27,brecorder.com
